US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Array Digital Infrastructure Inc.

38.12

0.0000

Volume:13.86K

Turnover:527.25K

Market Cap:3.29B

PE:6.16

High:38.13

Open:38.11

Low:37.85

Close:38.12

52wk High:60.82

52wk Low:33.71

Shares:86.38M

Float Shares:15.56M

Volume Ratio:0.39

T/O Rate:0.09%

Dividend:- -

Dividend Rate:- -

EPS(TTM):6.19

EPS(LYR):0.5551

ROE:22.68%

ROA:0.02%

PB:2.60

PE(LYR):68.68

Loading ...

Overview Company News Filings

Digitus Group Subsidiary Signs Addendum to Managed Services Agreement with Dubai's Du

New Topical Treatment Approval Signals Shift in Atopic Dermatitis Management Landscape

Digitus Group Appoints Kunal Dalmia as Group CFO

Micware Launches Growth Strategy Connecting Mobility and Digital Spaces with AI at its Core

Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference

CMS(867.HK/8A8.SG): Innovative Drug Lumirix® Approved in China for Additional Indication of Atopic Dermatitis (AD)

CMS Secures NMPA Nod for Ruxolitinib Cream's Expanded Use in Atopic Dermatitis

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

Telephone & Data Systems (TDS) Stock Jumps Nearly 8% After Ending a Deal for Array Digital Infrastructure (AD)

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

Digitus Group Says Wissam Farhat Resigns as CFO

Annovis to Host Corporate Update Webinar on September 2, 2026

LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease

Arcutis says Health Canada approves Zoryve cream 0.05% for children with AD

Array Digital Infra Price Target Cut to $45.00/Share from $54.00 by JP Morgan

U.S. Research Roundup-Cogent Communications, Dollar Tree, Home Depot

Kuwait's Digitus Group Q2 Loss 740,230 Dinars

Press Release: Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

Press Release: Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

GMO AD Partners Outlines Q2 2026 Results, Growth Strategy and Shareholder Returns

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/stock/AD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AD\",,,,,undefined,":{"symbol":"AD","market":"US","secType":"STK","nameCN":"Array Digital Infrastructure Inc.","latestPrice":38.12,"timestamp":1789395817227,"preClose":38.12,"halted":0,"volume":13861,"delay":0,"changeRate":0,"floatShares":15563300,"shares":86379877,"eps":6.185934,"marketStatus":"Trading","change":0,"latestTime":"09-14 10:23:50 EDT","open":38.105,"high":38.13,"low":37.845,"amount":527245.6882699999,"amplitude":0.007476,"askPrice":38.15,"askSize":20,"bidPrice":38.02,"bidSize":38,"shortable":3,"etf":0,"ttmEps":6.185934,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789416000000},"marketStatusCode":2,"adr":0,"exchange":"NYSE","adjPreClose":38.12,"postHourTrading":{"tag":"盘后","latestPrice":38.12,"preClose":38.12,"latestTime":"19:30 EDT","volume":1047,"amount":39911.64,"timestamp":1789169408128,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.386552,"impliedVol":0.3421,"impliedVolPercentile":0.596},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AD\",,,,,undefined,":{"symbol":"AD","floatShares":15563300,"roa":"0.02%","roe":"22.68%","lyrEps":0.555055,"volumeRatio":0.386552,"shares":86379877,"dividePrice":0,"high":38.13,"amplitude":0.007476,"preClose":38.12,"low":37.845,"week52Low":33.71,"pbRate":"2.60","psRate":"15.42","week52High":60.82,"institutionHeld":0.3358,"latestPrice":38.12,"committee":0.310345,"eps":6.185934,"divideRate":0,"volume":13861,"delay":0,"ttmEps":6.185934,"open":38.105,"prevYearClose":53.62,"prevWeekClose":38.12,"prevMonthClose":36.66,"prevQuarterClose":36.26,"fiveDayClose":38.5,"twentyDayClose":35.98,"sixtyDayClose":39.01,"dividendPayoutRate":40.52599213795753,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0.4274298457535774},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"AD","fiscalQuarterEnding":"2026/06","expectedEps":0.27,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.44},{"date":"2026-06-11","symbol":"AD","amount":11,"announcedDate":"2026-06-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-11","defaultRemindTime":1781184600000,"name":"Array Digital Infrastructure Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-25","payableDate":"2026-06-11","currency":"USD","dateTimestamp":1781150400000,"payDate":"2026-06-25"},{"market":"US","date":"2026-05-08","symbol":"AD","fiscalQuarterEnding":"2026/03","expectedEps":-0.06,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":0.42},{"market":"US","date":"2026-02-20","symbol":"AD","fiscalQuarterEnding":"2025/12","expectedEps":0.32,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771563600000,"reportTimeType":"pre","actualEps":0.48},{"date":"2026-01-23","symbol":"AD","amount":10.25,"announcedDate":"2026-01-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-23","defaultRemindTime":1769178600000,"name":"Array Digital Infrastructure Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-02","payableDate":"2026-01-23","currency":"USD","dateTimestamp":1769144400000,"payDate":"2026-02-02"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AD\",market:\"US\",,,undefined,":[{"executeDate":"2025-08-20","recordDate":"2025-08-11","paymentDate":"2025-08-19","value":23,"currency":"USD"},{"executeDate":"2026-01-23","recordDate":"2026-01-23","paymentDate":"2026-02-02","value":10.25,"currency":"USD"},{"executeDate":"2026-06-11","recordDate":"2026-06-11","paymentDate":"2026-06-25","value":11,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.2,"hold":0.6,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2,"analysts":5,"updateTime":1786420800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AD","date":"2026-09-11","current":6.162368,"percent":0.3,"low":-273.92211,"twenty":-174.161842,"median":21.222313,"eighty":260.167256,"high":320.844562,"avg":57.30785,"sd":169.935215,"marketCap":3290525950},"quantilePoints":[{"date":"2025-08-15","current":-273.850129,"twenty":-273.893318,"median":-273.850129,"eighty":-273.612593,"marketCap":6572403103},{"date":"2025-08-22","current":-200.933798,"twenty":-273.763753,"median":-273.490226,"eighty":-228.502362,"marketCap":4822411161},{"date":"2025-08-29","current":-194.49692,"twenty":-273.591,"median":-200.933798,"eighty":-194.626488,"marketCap":4667926077},{"date":"2025-09-05","current":-189.890035,"twenty":-273.511821,"median":-195.360711,"eighty":-192.519268,"marketCap":4557360841},{"date":"2025-09-12","current":-184.671298,"twenty":-272.73443,"median":-194.119011,"eighty":-189.199003,"marketCap":4432111159},{"date":"2025-09-19","current":-175.349555,"twenty":-256.070925,"median":-192.368109,"eighty":-183.778715,"marketCap":4208389313},{"date":"2025-09-26","current":-169.950862,"twenty":-200.271577,"median":-189.74607,"eighty":-179.092649,"marketCap":4078820677},{"date":"2025-10-03","current":-180.892213,"twenty":-197.170296,"median":-184.671298,"eighty":-177.638601,"marketCap":4341413113},{"date":"2025-10-10","current":-180.028422,"twenty":-195.252737,"median":-184.059446,"eighty":-177.861746,"marketCap":4320682131},{"date":"2025-10-17","current":-179.200623,"twenty":-194.756057,"median":-183.555568,"eighty":-177.18511,"marketCap":4300814940},{"date":"2025-10-24","current":-177.581015,"twenty":-194.345757,"median":-180.586287,"eighty":-177.242697,"marketCap":4261944349},{"date":"2025-10-31","current":-176.105372,"twenty":-193.617663,"median":-180.892213,"eighty":-177.242697,"marketCap":4226528922},{"date":"2025-11-07","current":-171.642452,"twenty":-192.972746,"median":-180.010426,"eighty":-176.702827,"marketCap":4119418849},{"date":"2025-11-14","current":241.378582,"twenty":-192.09564,"median":-179.920448,"eighty":-175.407141,"marketCap":3917333000},{"date":"2025-11-21","current":240.473745,"twenty":-190.782619,"median":-179.452562,"eighty":-172.916544,"marketCap":3902648400},{"date":"2025-11-28","current":261.764027,"twenty":-189.890035,"median":-179.056658,"eighty":-170.850644,"marketCap":4248168400},{"date":"2025-12-05","current":265.117247,"twenty":-189.602105,"median":-178.588771,"eighty":240.420519,"marketCap":4302587800},{"date":"2025-12-12","current":265.543053,"twenty":-189.098227,"median":-177.958923,"eighty":244.409875,"marketCap":4309498200},{"date":"2025-12-19","current":274.059166,"twenty":-184.671298,"median":-177.329076,"eighty":249.043083,"marketCap":4447706200},{"date":"2025-12-26","current":286.620433,"twenty":-184.613712,"median":-177.149119,"eighty":260.390804,"marketCap":4651563000},{"date":"2026-01-02","current":285.396241,"twenty":-184.556126,"median":-176.681232,"eighty":261.913059,"marketCap":4631695600},{"date":"2026-01-09","current":277.199482,"twenty":-183.965869,"median":-175.78145,"eighty":263.648217,"marketCap":4498670400},{"date":"2026-01-16","current":297.372025,"twenty":-183.569965,"median":-174.161842,"eighty":266.266922,"marketCap":4826050600},{"date":"2026-01-23","current":320.844562,"twenty":-183.555568,"median":-173.981886,"eighty":271.994008,"marketCap":5206986400},{"date":"2026-01-30","current":252.1834,"twenty":-183.238845,"median":-172.02036,"eighty":268.321434,"marketCap":4092684400},{"date":"2026-02-06","current":257.665648,"twenty":-182.648588,"median":-169.950862,"eighty":267.224985,"marketCap":4181655800},{"date":"2026-02-13","current":269.109175,"twenty":-182.115917,"median":238.717297,"eighty":267.224985,"marketCap":4367372800},{"date":"2026-02-20","current":267.938209,"twenty":-181.48247,"median":240.926164,"eighty":268.704659,"marketCap":4348369200},{"date":"2026-02-27","current":255.643071,"twenty":-181.064971,"median":244.409875,"eighty":267.842403,"marketCap":4148831400},{"date":"2026-03-06","current":262.668864,"twenty":-180.769843,"median":247.365175,"eighty":267.342081,"marketCap":4262853000},{"date":"2026-03-13","current":255.643071,"twenty":-180.229973,"median":249.043083,"eighty":266.671437,"marketCap":4148831400},{"date":"2026-03-20","current":82.941723,"twenty":-180.021224,"median":248.376453,"eighty":265.819826,"marketCap":4043906649},{"date":"2026-03-27","current":82.498564,"twenty":-179.985233,"median":245.210832,"eighty":265.628214,"marketCap":4022299967},{"date":"2026-04-02","current":84.413012,"twenty":-179.95644,"median":244.199544,"eighty":265.543053,"marketCap":4115640834},{"date":"2026-04-10","current":87.513828,"twenty":-179.920448,"median":240.447132,"eighty":265.117247,"marketCap":4266824209},{"date":"2026-04-17","current":87.691125,"twenty":-179.920448,"median":236.588268,"eighty":264.265636,"marketCap":4275468504},{"date":"2026-04-24","current":86.627343,"twenty":-179.596527,"median":87.806368,"eighty":264.052733,"marketCap":4223602732},{"date":"2026-05-01","current":88.098909,"twenty":-179.308596,"median":87.655666,"eighty":263.999507,"marketCap":4295350384},{"date":"2026-05-08","current":87.40745,"twenty":-179.200623,"median":87.575882,"eighty":263.414024,"marketCap":4261637632},{"date":"2026-05-15","current":21.135166,"twenty":-178.912692,"median":87.337865,"eighty":263.147896,"marketCap":4402539647},{"date":"2026-05-22","current":21.338509,"twenty":-178.876701,"median":86.919883,"eighty":263.041444,"marketCap":4444896694},{"date":"2026-05-29","current":21.222313,"twenty":-178.646357,"median":86.396857,"eighty":262.74338,"marketCap":4420692667},{"date":"2026-06-05","current":21.55845,"twenty":-178.444805,"median":85.972934,"eighty":262.32822,"marketCap":4490711460},{"date":"2026-06-12","current":16.645033,"twenty":-178.17847,"median":85.475751,"eighty":262.157897,"marketCap":3467226884},{"date":"2026-06-18","current":16.18855,"twenty":-177.926531,"median":85.370237,"eighty":262.136607,"marketCap":3372139635},{"date":"2026-06-26","current":14.893798,"twenty":-177.667394,"median":85.086615,"eighty":261.913059,"marketCap":3102437619},{"date":"2026-07-02","current":15.151088,"twenty":-177.480239,"median":84.907561,"eighty":261.764027,"marketCap":3156032250},{"date":"2026-07-10","current":14.416565,"twenty":-177.285886,"median":83.339562,"eighty":261.593705,"marketCap":3003028221},{"date":"2026-07-17","current":14.495412,"twenty":-177.192309,"median":82.498564,"eighty":261.253061,"marketCap":3019452383},{"date":"2026-07-24","current":14.184174,"twenty":-177.005154,"median":82.259257,"eighty":261.061448,"marketCap":2954620167},{"date":"2026-07-31","current":14.516162,"twenty":-176.767611,"median":81.532476,"eighty":260.944352,"marketCap":3023774530},{"date":"2026-08-07","current":14.794201,"twenty":-176.56606,"median":80.513209,"eighty":260.8379,"marketCap":3081691310},{"date":"2026-08-14","current":5.765224,"twenty":-176.069381,"median":21.824041,"eighty":260.742094,"marketCap":3087300300},{"date":"2026-08-21","current":5.739385,"twenty":-175.867829,"median":21.55845,"eighty":260.635642,"marketCap":3073463660},{"date":"2026-08-28","current":5.731311,"twenty":-175.579899,"median":21.315684,"eighty":260.358869,"marketCap":3069139710},{"date":"2026-09-04","current":6.254541,"twenty":-175.112012,"median":21.259662,"eighty":260.252418,"marketCap":3349331670},{"date":"2026-09-11","current":6.144727,"twenty":-174.161842,"median":21.222313,"eighty":260.167256,"marketCap":3290525950}],"updateTime":1789395830511},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667657804","title":"Digitus Group Subsidiary Signs Addendum to Managed Services Agreement with Dubai's Du","url":"https://stock-news.laohu8.com/highlight/detail?id=2667657804","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667657804?lang=en_us&edition=fundamental","pubTime":"2026-09-14 18:05","pubTimestamp":1789380342,"startTime":"0","endTime":"0","summary":"Sept 14 (Reuters) - DIGITUS GROUP FOR DIGITAL INFRASTRUCTURE, DATA CENTERS & COMMUNICATIONS KSCP::*DIGITUS GROUP - UAE SUBSIDIARY SIGNS ANNEX TO EXISTING MANAGED SERVICES AGREEMENT WITH DU*DIGITUS GRO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nRSD6RkT9Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","TDS","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165135911","title":"New Topical Treatment Approval Signals Shift in Atopic Dermatitis Management Landscape","url":"https://stock-news.laohu8.com/highlight/detail?id=1165135911","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165135911?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:26","pubTimestamp":1788956795,"startTime":"0","endTime":"0","summary":"On September 2, China Medical System Holdings Ltd (0867.HK), through its subsidiary Demei Pharma, received NMPA approval for ruxolitinib phosphate cream to add a new indication for atopic dermatitis...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","BK4200","TCS","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587027","title":"Digitus Group Appoints Kunal Dalmia as Group CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587027","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587027?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:27","pubTimestamp":1788953275,"startTime":"0","endTime":"0","summary":"Sept 9 (Reuters) - DIGITUS GROUP FOR DIGITAL INFRASTRUCTURE, DATA CENTERS & COMMUNICATIONS KSCP::*DIGITUS GROUP - APPOINTS KUNAL DALMIA AS GROUP CFO*Further company coverage: DIGITUS.KW* ((Reuters.Bri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nRSD21p2H7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","BK4132","TDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664363383","title":"Micware Launches Growth Strategy Connecting Mobility and Digital Spaces with AI at its Core","url":"https://stock-news.laohu8.com/highlight/detail?id=2664363383","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664363383?lang=en_us&edition=fundamental","pubTime":"2026-09-04 09:25","pubTimestamp":1788485100,"startTime":"0","endTime":"0","summary":"With its two platforms “micAuto” and “DynaPlanet”, Micware aims to evolve into a business where technology assets continuously create valueKOBE, Japan, Sept.  03, 2026 (GLOBE NEWSWIRE) -- Micware Co.,","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/04/3356354/0/en/micware-launches-growth-strategy-connecting-mobility-and-digital-spaces-with-ai-at-its-core.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IGM","VGT","VTHR","MWC","ARTY","AGIX","AIPO","BK4132","CHAT","QTOC","AD","BK4585","BK4097","QQH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664877186","title":"Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664877186","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664877186?lang=en_us&edition=fundamental","pubTime":"2026-09-03 21:15","pubTimestamp":1788441300,"startTime":"0","endTime":"0","summary":"MIAMI, Sept.  03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/03/3355999/0/en/longeveron-to-present-at-the-h-c-wainwright-28th-annual-global-investment-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4150","LGVN","BK4132","MSC","AD","BK4139","BK4575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664087717","title":"CMS(867.HK/8A8.SG): Innovative Drug Lumirix® Approved in China for Additional Indication of Atopic Dermatitis (AD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664087717","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664087717?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:08","pubTimestamp":1788437280,"startTime":"0","endTime":"0","summary":"SHENZHEN, CHINA, Sept.  03, 2026 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/03/3355884/0/en/cms-867-hk-8a8-sg-innovative-drug-lumirix-approved-in-china-for-additional-indication-of-atopic-dermatitis-ad.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNP33.GBP","SG9999015945.SGD","LU2488822045.USD","LU1223083913.SGD","LU1223082196.USD","IE00BMCWC346.EUR","BK1593","BK4017","BK4132","XME","SGDM","SG9999015986.USD","BK4200","SG9999015952.SGD","CDE","SG9999015978.USD","IE00BYV24P56.USD","BK1191","GDXJ","SG9999004220.SGD","IE00BVYPNQ40.USD","AD","TCS","LU1223082519.USD","00867","IE00BGHQDM52.EUR","SIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176808711","title":"CMS Secures NMPA Nod for Ruxolitinib Cream's Expanded Use in Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=1176808711","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176808711?lang=en_us&edition=fundamental","pubTime":"2026-09-03 18:04","pubTimestamp":1788429862,"startTime":"0","endTime":"0","summary":"CMS (00867) has announced that its subsidiary, Demei Pharma, obtained approval from China's National Medical Products Administration (NMPA) on September 2, 2026, for the New Drug Application (NDA) of...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK4132","BK1574","IE00BYV24P56.USD","SG9999004220.SGD","IE00BVYPNQ40.USD","IE00BVYPNP33.GBP","BK1191","SG9999015978.USD","SG9999015986.USD","IPOS","BK1161","LNGR","MEDX","SG9999015945.SGD","IE00BGHQDM52.EUR","LU2488822045.USD","IE00BMCWC346.EUR","06978","SG9999015952.SGD","IBBQ","159992","AD","00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664819849","title":"Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664819849","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664819849?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:00","pubTimestamp":1788379200,"startTime":"0","endTime":"0","summary":"NEWTON, Mass., Sept.  02, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amylo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3355470/0/en/acumen-pharmaceuticals-to-participate-in-upcoming-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","BK4139","BK4539","ABOS","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664144810","title":"Telephone & Data Systems (TDS) Stock Jumps Nearly 8% After Ending a Deal for Array Digital Infrastructure (AD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664144810","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664144810?lang=en_us&edition=fundamental","pubTime":"2026-09-02 22:44","pubTimestamp":1788360280,"startTime":"0","endTime":"0","summary":"Telephone & Data Systems stock was up nearly 8% on Wednesday after the company ended its bid to acquire Array Digital Infrastructure.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/telephone-data-systems-tds-stock-jumps-nearly-8-after-ending-a-deal-for-array-digital-infrastructure-ad?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/telephone-data-systems-tds-stock-jumps-nearly-8-after-ending-a-deal-for-array-digital-infrastructure-ad?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4132","AD","TDS","DTCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664558698","title":"Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses","url":"https://stock-news.laohu8.com/highlight/detail?id=2664558698","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664558698?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:00","pubTimestamp":1788260400,"startTime":"0","endTime":"0","summary":"Enrollment completed in KT-621 BROADEN2 Phase 2b AD trial with topline data expected by year-end 2026; Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3353950/0/en/kymera-therapeutics-announces-presentations-on-kt-621-a-first-in-class-oral-stat6-degrader-at-the-european-respiratory-society-and-european-academy-of-dermatology-venereology-congr.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0162691827.USD","LU0541502299.USD","BK4096","BP","KT","BK4139","KYMR","LU1162221912.USD","LU0300736062.USD","AD","BK4585","LU0072461881.USD","BK4115","LU0320765646.SGD","EPV","BK4132","LU0541501648.USD","PN","LU1829250122.USD","BK4201","BK4588","LU0300736492.USD","BPH","LU0006061336.USD","SG9999004220.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662569716","title":"Digitus Group Says Wissam Farhat Resigns as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2662569716","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662569716?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:58","pubTimestamp":1787745483,"startTime":"0","endTime":"0","summary":"Aug 26 (Reuters) - DIGITUS GROUP FOR DIGITAL INFRASTRUCTURE, DATA CENTERS & COMMUNICATIONS::*DIGITUS GROUP - WISSAM FARHAT RESIGNS AS CFO, EFFECTIVE AUG 31*Further company coverage: DIGITUS.KW* ((Reut","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nRSD5gC5Mv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","TDS","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662509732","title":"Annovis to Host Corporate Update Webinar on September 2, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662509732","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662509732?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:00","pubTimestamp":1787659200,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Aug.  25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/25/3350406/0/en/annovis-to-host-corporate-update-webinar-on-september-2-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","ANVS","BK4585","BK4218","HST","AD","BK4139","BK4132","LU1169590202.USD","PD","BK4023","BK4588","BK4181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661327966","title":"LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2661327966","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661327966?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:04","pubTimestamp":1787573040,"startTime":"0","endTime":"0","summary":"LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.)TOKYO and CAMBRIDGE, Mass., Aug.  24, 2026 (GLOBE N","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/24/3349698/0/en/leqembi-iqlik-lecanemab-irmb-autoinjector-for-initiation-of-therapy-now-available-in-the-u-s-for-early-alzheimer-s-disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","CAA","CDR","BK4080","AD","ARIA","MCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661940239","title":"Arcutis says Health Canada approves Zoryve cream 0.05% for children with AD","url":"https://stock-news.laohu8.com/highlight/detail?id=2661940239","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661940239?lang=en_us&edition=fundamental","pubTime":"2026-08-21 01:30","pubTimestamp":1787247037,"startTime":"0","endTime":"0","summary":"Arcutis Canada announced that Health Canada has approved ZORYVE cream 0.05% for the topical treatment of mild to moderate atopic dermatitis in pedi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arcutis-says-health-canada-approves-zoryve-cream-0-05-for-children-with-ad-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arcutis-says-health-canada-approves-zoryve-cream-0-05-for-children-with-ad-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AD","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660044420","title":"Array Digital Infra Price Target Cut to $45.00/Share from $54.00 by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2660044420","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660044420?lang=en_us&edition=fundamental","pubTime":"2026-08-20 03:12","pubTimestamp":1787166720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AD/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660438984","title":"U.S. Research Roundup-Cogent Communications, Dollar Tree, Home Depot","url":"https://stock-news.laohu8.com/highlight/detail?id=2660438984","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660438984?lang=en_us&edition=fundamental","pubTime":"2026-08-19 15:50","pubTimestamp":1787125815,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Cogent Communications, Dollar Tree, Home DepotAug 19 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nL4N44G0KE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TDS","RTH","MD","ARMK","CCOI","HOMZ","WDGF","MCK","RSPS","SHLD","EVX","AD","TRUM","VEGI","MRCY","FTAG","FOWF","CAH","NOC","FSPC","D","HD","PKB","AGCO","GPN","BPAY","IDEF","HWAY","ELF","BZZ","BAND","CGW","HSIC","KROP","SEPN","SPSC","HONA","AMLX","SJM","NUKX","MADE","TBLU","DE","COR","KEYS","ONCY","ZAP","ECL","DLTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659171711","title":"Kuwait's Digitus Group Q2 Loss 740,230 Dinars","url":"https://stock-news.laohu8.com/highlight/detail?id=2659171711","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659171711?lang=en_us&edition=fundamental","pubTime":"2026-08-16 14:06","pubTimestamp":1786860366,"startTime":"0","endTime":"0","summary":"Aug 16 (Reuters) - DIGITUS GROUP FOR DIGITAL INFRASTRUCTURE, DATA CENTERS & COMMUNICATIONS::*DIGITUS GROUP Q2 NET LOSS ATTRIBUTABLE 740,230 DINARS*DIGITUS GROUP Q2 TOTAL OPERATING REVENUE 6.9 MILLION ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260816:nRSD1zTVcD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TDS","AD","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659099146","title":"Press Release: Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2659099146","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659099146?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:01","pubTimestamp":1786708860,"startTime":"0","endTime":"0","summary":"-- Pivotal Phase 3 Alzheimer's disease  trial is fully enrolled with a. total number of 850 patients, exceeding original projections.-- Parkinson's disease  open-label extension  study has enrolled. 266 patients with full enrollment projected in Q4 2026.-- Annovis will host a corporate update webinar on Wednesday, September 2,-- Patients: The pivotal Phase 3 AD trial includes patients diagnosed with. early AD  who are also positive for plasma pTau217 biomarker,confirming the presence of amyloid and tau pathology in the brain.-- Study design: The study measures cognition  and function. pTau217, and other biomarkers to evaluate changes in disease pathology.The study is designed to test both symptomatic  and. -- Timeline: The Company plans a database lock for the 6-month analysis in. Q1 2027, with the top-line symptomatic data readout anticipated in the. same quarter. The disease-modifying data readout is expected a year. later.Alzheimer's disease -- OLE study-- Start: The AD OLE study is","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","LU1169589451.USD","PD","DBS","BK4023","BK4139","BK4132","AD","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659145881","title":"Press Release: Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659145881","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659145881?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:00","pubTimestamp":1786705200,"startTime":"0","endTime":"0","summary":"president and chief executive officer and a member of the Board of. Directors. Co-founder Paul L. Berns, will serve as Executive Chair.-- Dr. Pinto has made significant contributions to Neumora since. joining in 2021, having served in roles of increasing","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NMRA","AD","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659116374","title":"GMO AD Partners Outlines Q2 2026 Results, Growth Strategy and Shareholder Returns","url":"https://stock-news.laohu8.com/highlight/detail?id=2659116374","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659116374?lang=en_us&edition=fundamental","pubTime":"2026-08-14 14:59","pubTimestamp":1786690743,"startTime":"0","endTime":"0","summary":"The latest update is out from GMO AD Partners Inc. ( ($JP:4784) ). GMO AD Partners Inc., under the GMO Internet umbrella, reported its financial re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gmo-ad-partners-outlines-q2-2026-results-growth-strategy-and-shareholder-returns?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gmo-ad-partners-outlines-q2-2026-results-growth-strategy-and-shareholder-returns?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GMO","BK4132","AD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":190,"code":"91000000","status":"200"}]}}